

THERAPEUTIC HOTLINE

Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma

Linton Figueiredo Souza* & Simone Trancoso Souza†

**Infectious Disease Research Center, University Hospital Clemente Faria – Montes Claros State University and †Campus Darcy Ribeiro – Montes Claros State University*

ABSTRACT: The effectiveness of intense pulsed light (IPL) has been reported in adults with melasma, but there is little information about IPL with triple combination topical therapy (TC) and refractory melasma. Sixty-two patients with totally or partially refractory melasma were enrolled in this randomized open-label study. Thirty-one patients were treated with IPL in a single session, bleaching agents and broad-spectrum sunscreens. Thirty-one patients were in the control group, receiving only bleaching agents and broad-spectrum sunscreens. The Melasma Area and Severity Index (MASI) and the investigator's global assessment using a seven-point scale were used to determine the impact and effectiveness of the treatment. The IPL group results based on MASI showed a 49.4% reduction (from 17.6 to 8.9; $p < 0.001$) after six months and a 44.9% reduction after 12 months (from 17.6 to 9.7; $p < 0.001$). The investigator's global assessment showed that the difference in the improvement rate between the IPL group and control group was significant ($p = 0.002$), with a better response in the IPL group. Single session IPL combined with stable fixed-dose triple combination treatment is a safe and effective treatment for refractory mixed and dermal melasma.

KEYWORDS: dermal melasma, mixed melasma, treatment

Introduction

Intense pulsed light (IPL) is a noncoherent broad-spectrum light, ranging from 500 to 1200 nm, permitting the treatment of multiple conditions (1,2). For pigment disorders, IPL is associated with fewer photothermal injuries and fewer side effects than laser (3–5). Melasma is classified according to clinical

and histological features. The location of the pigment can be epidermal, dermal, or mixed. This classification is particularly important to define the therapeutic choice and the prognosis (3,4). Routine treatment, including broad-spectrum sunscreens, and bleaching agents, such as hydroquinone, tretinoin, and chemical peels, have shown satisfactory results in patients with epidermal melasma (4). Nevertheless, patients with dermal or mixed-type melasma are therapeutically challenging (6). A previous study has indicated the use of IPL in refractory melasma, showing a therapeutic success rate of 70–77% (4,6). The present study aims to clarify the effect of IPL on melasma refractory to

Address correspondence and reprint requests to: Linton Wallis Figueiredo Souza, MD, Master in Health Sciences, University Hospital Clemente Faria, Av. Cula Mangabeira, 562 Montes Claros, Minas Gerais, Brazil 39401-001, or email: wallis@uai.com.br.

stable fixed-dose triple combination treatment (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) in skin phototypes II–V.

Patients and methods

Sixty-two patients with melasma totally or partially resistant to 6 months of treatment with combined bleaching agents were enrolled in this randomized, evaluator-blinded, open-label study. Patients with mixed or dermal melasma, phototypes II–V, resistant to the triple combination treatment (TC) were included. All patients were assessed by dermoscopy (video dermatoscope, Castells, Sao Paulo, Brazil). Melasma was considered to be of the epidermal type (brownish homogeneous pigmentation and a regular pigmented network), the dermal type (bluish gray pigmentation and an irregular network), or mixed (areas presenting both features) (7). The exclusion criteria for the present study included pregnancy, patients with epidermal melasma, lactation, use of oral contraceptives, hormone replacement therapy, potentially photosensitizing drugs, and major outdoor activities. Patients underwent a clinical evaluation using the Melasma Area and Severity Index (MASI) (8,9). An investigator's global assessment of improvement was used, which was based on a 7-point scale, from 1 (worst) to 7 (clear). The investigator's global assessment and MASI readings were taken by the same investigators at each time point. All patients were assigned with individual identification numbers and were randomly and equally divided into two groups (IPL and control) using a random numbers table. Thirty-one patients in the IPL group were treated with IPL with a cooling device, real-time calibration, and automatic pulse (Limelight, Cutera, Brisbane, CA, USA) in a single session with a filter of 560 nm and fluencies ranging from 12 to 22 J to skin phototypes II–V. Most patients complained of mild to moderate pain and a burning sensation. Immediately after treatment, some mild, transient erythema was present. This was followed by slight darkening of the pigmented lesions, the gold standard indication of the treatment. IPL group patients developed microcrusts and were treated with fusidic acid associated with Betamethasone Valerate Cream, aciclovir 400 mg/day for 10 days, deflazacort 30 mg/day for 5 days, and broad-spectrum sunscreens until disappearance, which occurred between 1 and 2 weeks. Then, the use of bleaching agents (stable fixed-dose triple combination treatment) that had previously been totally or partially refractory was restarted in IPL group as a means of

avoiding possible repigmentation. Evaluations by MASI were performed in the first and sixth months and, later, a final evaluation was performed at the end of the twelfth month. Thirty-one patients were in the control group, receiving only triple combination treatment and broad-spectrum sunscreens. Statistical analysis was performed using *t*-tests, paired *t*-tests. All values were expressed as means $\pm$ standard deviation (SD). A *p* value less than 0.05 was considered as statistically significant. Informed consent was obtained. The present study was conducted according to the Declaration of Helsinki.

Results

A total of 62 patients (58 women and 4 men; mean $\pm$ SD age 44.3 ± 6.1 years) were evaluated in the study. The variables of age, phototypes II, III, IV, or V, type of refractory melasma (mixed or dermal), and dura-

Table 1. Characteristic of refractory melasma patients and treatment response

Data	Group	
	Intense pulsed light	Control

of patients being clear or almost clear after 8 weeks of treatment (6). The present study showed that single-session IPL followed by TC was more effective than TC cream therapy alone for mixed and dermal melasma treatment. Additionally, the correct use of bleaching agents only in pigmented areas, avoiding contact with normal skin as much as possible, facilitates the use of IPL in refractory melasmas. The improvement after one session of IPL was 49.4%, significantly higher when compared with another study that showed an improvement of 24.9% compared with baseline (4). The use of TC after the disappearance of microcrusts reduced treatment failure compared with another study (4). Nevertheless, patients with frontal and malar melasma showed a poor response, and patients with melasma without the presence of lesions on the forehead showed a statistically significant

improvement. The present study showed a lower frequency of excellent improvement (almost clear and clear) than can be found in the literature, probably due to the use of a single IPL session (10). The MASI scores revealed the effectiveness of IPL in treating pigmented lesions of low and high contrasts with promising results. Effective treatments in Hispanics and Asians have been performed using IPL with few adverse effects (5,11). Furthermore, other treatments, such as Er:YAG lasers, dermabrasion, ultrapulse CO₂ lasers, and fractional lasers, have demonstrated effects on melasma. Nevertheless, they are more aggressive or high-cost methods, a larger number of sessions are required to obtain satisfactory results, and there tends to be in some cases the occurrence of persistent erythema, post-inflammatory hyperpigmentation, or scarring (12–15).



FIG. 1. Clinical results after single session of treatment with intense pulsed light combined with stable fixed-dose triple combination topical therapy. (a) Baseline; (b) 7 days – microcrust formation; (c) 6 months – moderate improvement; (d) 12 months – marked improvement.

In conclusion, single-session IPL combined with stable fixed-dose triple combination treatment is a safe and effective treatment for refractory mixed and dermal melasma. Patients with frontal and malar melasma showed a poor response, and patients with melasma without the presence of lesions on the forehead showed a statistically significant improvement. IPL stands out as an effective tool in the refractory melasma treatment, with minimal side effects when done under the correct conditions.

References

1. Dierickx CC, Anderson RR. Visible light treatment of photo-aging. *Dermatol Ther* 2005; **18**: 191–208.
2. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. *J Am Acad Dermatol* 2011; **65** (4): 699–714.
3. Wind BS, Kroon MW, Meesters AA, et al. Non-ablative 1550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. *Lasers Surg Med* 2010; **42** (7): 607–612.
4. Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the treatment of refractory melasma in Asian persons. *Dermatol Surg* 2004; **30**: 1196–1200.
5. Li YH, Chen JZ, Wei HC, et al. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients. *Dermatol Surg* 2008; **34** (5): 693–700.
6. Goldman MP, Gold MH, Palm MD, et al. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma. *Dermatol Surg* 2011; **37** (2): 224–233.
7. Tamler C, Fonseca RMB, Pereira FBC, Barcauí CB. Classificação do melasma pela dermatoscopia: estudo comparativo com lâmpada de Wood. *Surg Cosmet Dermatol* 2009; **1** (3): 115–119.
8. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. *Arch Dermatol* 1994; **130** (6): 727–733.
9. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. *Br J Dermatol* 2003; **149** (3): 572–577.
10. Zoccali G, Piccolo D, Allegra P, Giuliani M. Melasma treated with intense pulsed light. *Aesthetic Plast Surg* 2010; **34**: 486–493.
11. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. *Semin Cutan Med Surg* 2009; **28**: 77–85.
12. Kodali S, Guevara IL, Carrigan CR, et al. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. *J Am Acad Dermatol* 2010; **63**: 1030–1035.
13. Katz TM, Glaich AS, Goldberg LH, Firoz BF, Dai T, Friedman PM. Treatment of melasma using fractional photothermolysis: a report of eight cases with long-term follow-up. *Dermatol Surg* 2010; **36**: 1273–1280.
14. Kang HY, Ortonne JP. What should be considered in treatment of melasma. *Ann Dermatol* 2010; **22**: 373–378.
15. Chan NP, Ho SG, Shek SY, Yeung CK, Chan HH. A case series of facial depigmentation associated with low fluence Q-switched 1064 nm Nd:YAG laser for skin rejuvenation and melasma. *Lasers Surg Med* 2010; **42** (8): 712–719.